Baseline Patient Characteristics, Comorbidities, Prior Medication Use, and Reasons for Dupilumab Initiation in Adult Patients in Russia With Atopic Dermatitis: Real-World Insights Into the GLOBOSTAD Multinational Prospective Observational Study ⋆ Вестник аллерголога-иммунолога
Baseline Patient Characteristics, Comorbidities, Prior Medication Use, and Reasons for Dupilumab Initiation in Adult Patients in Russia With Atopic Dermatitis: Real-World Insights Into the GLOBOSTAD Multinational Prospective Observational Study

Baseline Patient Characteristics, Comorbidities, Prior Medication Use, and Reasons for Dupilumab Initiation in Adult Patients in Russia With Atopic Dermatitis: Real-World Insights Into the GLOBOSTAD Multinational Prospective Observational Study

28.11.2023
44 0
ФИО: Daria S. Fomina
Соавторы: Daria S. Fomina1,2,3, Konstantin Raznatovsky4, Natalia Makhneva5, Jiangming Wu6, Marius Ardeleanu7, Kwinten Bosman8
Направление: Дерматология
Название учреждения: 1City Clinical Hospital No. 52, Moscow, Russian Federation; 2I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russian Federation; 3Astana Medical University, Kazakstan; 4North-Western State Medical University, Saint- Petersburg, Russian Federation; 5Medical Center Stels, Moscow, Russian Federation; 6Sanofi, Bridgewater, NJ, USA; 7Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA; 8Sanofi, Amsterdam, Netherlands
Страна: Russia
Город: Moscow
Телефон: +7 (916) 597-18-06
Почта: daria.s.fomina@gmail.com
 
Baseline Patient Characteristics, Comorbidities, Prior Medication Use, and Reasons for Dupilumab Initiation in Adult Patients in Russia With Atopic Dermatitis: Real-World Insights Into the GLOBOSTAD Multinational Prospective Observational Study
 
Daria S. Fomina1,2,3, Konstantin Raznatovsky4, Natalia Makhneva5, Jiangming Wu6, Marius Ardeleanu7, Kwinten Bosman8
 
1City Clinical Hospital No. 52, Moscow, Russian Federation; 2I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russian Federation; 3Astana Medical University, Kazakstan; 4North-Western State Medical University, Saint-Petersburg, Russian Federation; 5Medical Center Stels, Moscow, Russian Federation; 6Sanofi, Bridgewater, NJ, USA; 7Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA; 8Sanofi, Amsterdam, Netherlands
 
Comprehensive real-world data on patients with moderate-to-severe atopic dermatitis (AD) receiving novel systemic treatments in Russia are limited. This analysis reports demographics, comorbidities and prior medication use at baseline in patients with moderate-to-severe AD patients
in Russia from the GLOBOSTAD registry. This 5-year, international, non-interventional study (GLOBOSTAD; NCT03992417) included patients aged ≥12 years with moderate-to-severe AD who initiated dupilumab treatment based on country-specific prescribing criteria. Data reported are for the population at baseline (data cut-off: July 2023).
 
A total of 46 Russian patients enrolled in the study, 69.6% were 18-39 years old and 30.4% were 40–64 years old, with a mean (standard deviation) age of 33.7 (11.4) years. At enrollment, 93.5% of patients had a previous history of type 2 inflammatory comorbidities, consisting mainly of
food allergies (82.6%), allergic rhinitis (65.2%), asthma (65.2%), and allergic conjunctivitis (69.6%). For a total of 45.7% of patients, the use of systemic treatments in the form of non-steroidal immunosuppressants (8.7%) and corticosteroids (39.1%) were reported for treating AD within the past 12 months before enrollment. While for 91.3% of patients, the use of non-systemic treatment in the form of topical corticosteroids (69.6%) and topical calcineurin inhibitors (13%) were reported for treating AD within the past 12 months before enrollment. The reasons for dupilumab treatment initiation were previous treatment failure (84.8%), AD exacerbation (6.5%), or initiation as maintenance treatment (8.7%).
 
Type 2 inflammatory comorbidities were present in nearly all of the patients enrolled in Russia in the GLOBOSTAD observational study. Most of the patients had used systemic and/or non-systemic AD treatments in the 12 months preceding dupilumab initiation. In most patients,
dupilumab treatment was initiated due to previous treatment failure. These baseline demographics are consistent with the overall GLOBOSTAD baseline demographics[1].
 
References
1. Calzavara-Pinton P., et al. Adv Ther (2023).
 
Acknowledgments and funding sources
Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc. ClinicalTrials.gov Identifier: NCT03992417. Medical writing/editorial assistance was provided by Mark C. Howell, Jr., PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice guideline.
 
Disclosures
DF: CSL Behring, Novartis, Sanofi, Shire – honoraria. KR: Sanofi, Abbvie, Galleria, LeoPharma, Novartis, Eli Lilly, Janssen – speaker. NM: AbbVie, Lilly, Janssen, LEO Pharma, Novartis, Sanofi, Galderma, Amgen, Pfizer, Sanofi – speaker; Sanofi – investigator. JW, KB: Sanofi – employees, may hold stock and/or stock options in the company. AM: Regeneron Pharmaceuticals, Inc. – employee and shareholder.

Комментарии (0)

Читайте также

layСенсибилизация к splA протеиназе золотистого стафилококка у больных аллергическим ринитом и атопической бронхиальной астмой

Сенсибилизация к splA протеиназе золотистого стафилококка...

ФИО: Тюрин Юрий Александрович 1,заведующий лабораторией иммунологии и разработки аллергенов, ведущий научный сотрубник доктор медицинских наук
Соавторы: Фассахов Рустэм Салахович2,...

28.11.2023
80 0
layМаркировка пищевых продуктов: надеяться ли на производителя?

Маркировка пищевых продуктов: надеяться ли на производителя?

ФИО: Магбулова Нигора Алижоновна
Соавторы: Магбулова Нигора Алижоновна, Левицкая Юлия Владимировна, Джамбекова Гульнара Сулеймановна, Айметова Шахло Каримовна, Ким Светлана Александровна,...

28.11.2023
72 0

Новости

ЧИТАТЬ ДАЛЕЕ

Статьи

ЧИТАТЬ ДАЛЕЕ

Мероприятия

ВСЕ МЕРОПРИЯТИЯ

Газета

Содержание № 19-20/2023
Содержание № 19-20/2023

    АРХИВ НОМЕРОВ
    Авторы номера
    • Автор: Наталья Ивановна Ильина


      доктор медицинских наук, профессор, генеральный директор Российской ассоциации аллергологов и клинических иммунологов (РААКИ), заместитель директора по клинической работе ФГБУ «ГНЦ Институт иммунологии» ФМБА России

    • Автор: Авторы номера

    ВСЕ АВТОРЫ

    База знаний

    ЧИТАТЬ ДАЛЕЕ
    Этот сайт использует файлы cookie. Продолжая просматривать сайт, вы подтверждаете, что были проинформированы об использовании файлов cookie сайтом и согласны с нашими условиями обработки и хранения персональных данных.
    Подтвердить
    Отклонить
    Политика конфиденциальности